Core Viewpoint - Arcosa (ACA) reported quarterly earnings of $1.27 per share, exceeding the Zacks Consensus Estimate of $1.05 per share, and showing an increase from $0.91 per share a year ago [1][2] Financial Performance - The earnings surprise for the quarter was +20.95%, with the company previously expected to earn $0.29 per share but actually earning $0.49, resulting in a surprise of +68.97% [2] - Arcosa's revenues for the quarter were $736.9 million, which missed the Zacks Consensus Estimate by 2.09%, compared to $664.7 million in the same quarter last year [3] - Over the last four quarters, the company has surpassed consensus EPS estimates three times but has only topped revenue estimates once [3] Stock Performance - Arcosa shares have declined approximately 12.5% since the beginning of the year, while the S&P 500 has gained 7.9% [4] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.32 on revenues of $778.3 million, and for the current fiscal year, it is $3.83 on revenues of $2.93 billion [8] - The outlook for the industry, specifically the Building Products - Miscellaneous sector, is currently in the bottom 37% of over 250 Zacks industries, which may impact stock performance [9]

Company Performance - Karat Packing (KRT) reported quarterly earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.60 per share, but showing an increase from $0.49 per share a year ago, resulting in an earnings surprise of -5.00% [1] - The company posted revenues of $123.99 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.01%, and an increase from $112.6 million year-over-year [2] - Over the last four quarters, Karat Packing has surpassed consensus EPS estimates only once [2] Stock Outlook - The stock has underperformed the market, losing about 10.9% since the beginning of the year, while the S&P 500 gained 7.9% [3] - The current consensus EPS estimate for the coming quarter is $0.45 on revenues of $125 million, and for the current fiscal year, it is $1.59 on revenues of $462 million [7] Industry Context - The Containers - Paper and Packaging industry, to which Karat Packing belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Vermilion Energy reported a quarterly loss of $0.2 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.06, representing an earnings surprise of -233.33% [1] - The company posted revenues of $320.77 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 26.71%, and down from $350.04 million a year ago [2] - Over the last four quarters, Vermilion has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Movement and Outlook - Vermilion shares have declined approximately 16.4% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for understanding future stock performance, with current consensus EPS estimates at $0.07 for the coming quarter and $0.29 for the current fiscal year [4][7] Industry Context - The Oil and Gas - Exploration and Production - International industry, to which Vermilion belongs, is currently ranked in the bottom 18% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Vermilion's stock performance [5]

Company Performance - Verastem reported a quarterly loss of $0.39 per share, which was better than the Zacks Consensus Estimate of a loss of $0.85, representing an earnings surprise of +54.12% [1] - The company posted revenues of $2.14 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 86.36%, compared to revenues of $10 million a year ago [2] - Over the last four quarters, Verastem has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Movement and Outlook - Verastem shares have increased by approximately 10.6% since the beginning of the year, outperforming the S&P 500's gain of 7.9% [3] - The future stock price movement will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.72 on revenues of $10.98 million, and for the current fiscal year, it is -$3.51 on revenues of $17.25 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Verastem belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Verastem's performance [5]

Company Performance - Chesapeake Utilities reported quarterly earnings of $1.04 per share, exceeding the Zacks Consensus Estimate of $1 per share, and up from $0.86 per share a year ago, representing an earnings surprise of +4.00% [1] - The company posted revenues of $192.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.99%, compared to $166.27 million in the same quarter last year [2] - Over the last four quarters, Chesapeake Utilities has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Market Performance - Chesapeake Utilities shares have declined approximately 0.7% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's current Zacks Rank is 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.88 on revenues of $162.9 million, and for the current fiscal year, it is $6.27 on revenues of $885.2 million [7] - The outlook for the Utility - Gas Distribution industry is positive, currently ranking in the top 20% of over 250 Zacks industries, suggesting that the industry is likely to outperform the bottom 50% by a factor of more than 2 to 1 [8]

Core Viewpoint - AbCellera Biologics Inc. reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, indicating a positive earnings surprise of +29.41% [1] Financial Performance - The company posted revenues of $17.08 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 146.95%, compared to $7.32 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times [2] Stock Performance - AbCellera shares have increased approximately 40.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $7.31 million, and for the current fiscal year, it is -$0.69 on revenues of $25.53 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Kura Oncology reported a significant quarterly loss of $0.75 per share, which was much worse than the Zacks Consensus Estimate of $0.15, indicating a negative earnings surprise of -600.00% [1] Financial Performance - The company posted revenues of $15.29 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 89.23%, compared to zero revenues a year ago [2] - Kura Oncology has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Kura Oncology shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.56 on revenues of $59.35 million, and for the current fiscal year, it is -$1.31 on revenues of $229.86 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kura Oncology belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Company Performance - Globus Medical reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.76 per share, and up from $0.75 per share a year ago, representing an earnings surprise of +13.16% [1] - The company posted revenues of $745.34 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.49%, and an increase from $629.69 million year-over-year [2] - Over the last four quarters, Globus Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance and Outlook - Globus Medical shares have declined approximately 36.1% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $0.81 on revenues of $732.08 million, and for the current fiscal year, it is $3.17 on revenues of $2.84 billion [7] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]

Core Insights - Pinterest reported quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share, but showing an increase from $0.29 per share a year ago, resulting in an earnings surprise of -2.94% [1] - The company posted revenues of $998.23 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.42% and showing a year-over-year increase from $853.68 million [2] - Pinterest shares have increased approximately 34.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.43 on revenues of $1.02 billion, and for the current fiscal year, it is $1.83 on revenues of $4.16 billion [7] - The estimate revisions trend for Pinterest was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Internet - Software industry, to which Pinterest belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - VAREX IMAGING reported quarterly earnings of $0.18 per share, significantly exceeding the Zacks Consensus Estimate of $0.04 per share, marking an earnings surprise of +350.00% [1][2] Financial Performance - The company achieved revenues of $203 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.73%, although this represents a decline from year-ago revenues of $209.1 million [2] - Over the last four quarters, VAREX IMAGING has consistently surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] Stock Performance - VAREX IMAGING shares have declined approximately 51.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The current Zacks Rank for VAREX IMAGING is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $199.03 million, while the estimate for the current fiscal year is $0.42 on revenues of $801.93 million [7] - The trend of estimate revisions for VAREX IMAGING was mixed prior to the earnings release, which may change following the recent results [6] Industry Context - The Medical - Products industry, to which VAREX IMAGING belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8]